Gliomas are the most common primary tumors of the central nervous system. The molecular determinants of gliomas progression are still under investigation. p53 plays a major role in more than 50% of human cancers, among which are gliomas. In addition to this, the Murine-Double-Minute 2 (MDM2) gene was found to be amplified in about 10-15% of malignant gliomas. Genetic polymorphisms in MDM2 can modulate MDM2 expression, thereby impacting p53 tumor suppression and cause increased tumor progression. The aim of the current study is to verify the role played by each of MDM2 and p53 gene polymorphisms in glioma tumorigenesis, and the potential relation between both polymorphisms. Genotyping of the candidate genes was performed by PCR-RFLP assay in 45 glioma patients and 50 subjects as a control group. Serum p53 level was assayed by ELISA. The present study has shown that the genotype distributions of p53 Arg72Pro between glioma cases and control groups did not differ as well as their variant allele frequencies between cases and controls. As for MDM2 SNP309, our results support the hypothesis that there is no association between it and glioma tumorigenesis. Furthermore, there was no significant association detected between both p53 and MDM2 polymorphisms and glioma tumorigenesis.